Search Results - "Clavell, A."

Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 by VROOMAN, Lynda M, STEVENSON, Kristen E, LAVERDIERE, Caroline, LIPSHULTZ, Steven E, MICHON, Bruno, SCHORIN, Marshall, RELLING, Mary V, COHEN, Harvey J, NEUBERG, Donna S, SALLAN, Stephen E, SILVERMAN, Lewis B, SUPKO, Jeffrey G, O'BRIEN, Jane, DAHLBERG, Suzanne E, ASSELIN, Barbara L, ATHALE, Uma H, CLAVELL, Luis A, KELLY, Kara M, KUTOK, Jeffery L

“…We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents…”
Get full text

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes by LIPSHULTZ, Steven E, MILLER, Tracie L, ASSELIN, Barbara L, ATHALE, Uma H, CLAVELL, Luis A, LAVERDIERE, Caroline, MICHON, Bruno, SCHORIN, Marshall A, SALLAN, Stephen E, SCULLY, Rebecca E, LIPSITZ, Stuart R, RIFAI, Nader, SILVERMAN, Lewis B, COLAN, Steven D, NEUBERG, Donna S, DAHLBERG, Suzanne E, HENKEL, Jacqueline M

“…Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help…”
Get full text

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l -asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial by Place, Andrew E, MD, Stevenson, Kristen E, MS, Vrooman, Lynda M, MD, Harris, Marian H, MD, Hunt, Sarah K, MPH, O'Brien, Jane E, BA, Supko, Jeffrey G, PhD, Asselin, Barbara L, MD, Athale, Uma H, MD, Clavell, Luis A, Prof, Cole, Peter D, MD, Kelly, Kara M, Prof, Laverdiere, Caroline, MD, Leclerc, Jean-Marie, MD, Michon, Bruno, MD, Schorin, Marshall A, Prof, Welch, Jennifer J G, MD, Lipshultz, Steven E, Prof, Kutok, Jeffery L, MD, Blonquist, Traci M, MS, Neuberg, Donna S, ScD, Sallan, Stephen E, Prof, Silverman, Lewis B, Dr

“…Summary Background l -asparaginase is a universal component of treatment for childhood acute lymphoblastic leukaemia, and is usually administered…”
Get full text

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial by Lipshultz, Steven E, Prof, Scully, Rebecca E, BA, Lipsitz, Stuart R, ScD, Sallan, Stephen E, Prof, Silverman, Lewis B, MD, Miller, Tracie L, Prof, Barry, Elly V, MD, Asselin, Barbara L, MD, Athale, Uma, MD, Clavell, Luis A, MD, Larsen, Eric, MD, Moghrabi, Albert, MD, Samson, Yvan, MD, Michon, Bruno, MD, Schorin, Marshall A, Prof, Cohen, Harvey J, Prof, Neuberg, Donna S, ScD, Orav, E John, PhD, Colan, Steven D, Prof

“…Summary Background Doxorubicin chemotherapy is associated with cardiomyopathy. Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children…”
Get full text

Intrinsic Myocardial Function and Relationship with Left Ventricular Unloading in Patients Supported on CF-LVAD Therapy by Rosenbaum, A.N., Soldatova, A., Stulak, J.M., Clavell, A., Behfar, A.

“…Despite strong interest in left ventricular recovery, no clinical data exist on the relationship between intrinsic myocardial function and reverse remodeling…”
Get full text

Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study by Ladas, Elena J., Ph.D, Orjuela, Manuela, M.D, Stevenson, Kristen, M.S, Cole, Peter D., M.D, Lin, Meiko, M.A, Athale, Uma H., M.D, Clavell, Luis A., M.D, Leclerc, Jean-Marie, M.D, Michon, Bruno, M.D, Schorin, Marshall A., M.D, Welch, Jennifer Greene, M.D, Asselin, Barbara L., M.D, Sallan, Stephen E., M.D, Silverman, Lewis B., M.D, Kelly, Kara M., M.D

“…Abstract Objective Children with acute lymphoblastic leukemia (ALL) are at elevated risk for nutrition-related morbidity both during and after therapy. We…”
Get full text

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001 by Vrooman, Lynda M., Blonquist, Traci M., Harris, Marian H., Stevenson, Kristen E., Place, Andrew E., Hunt, Sarah K., O'Brien, Jane E., Asselin, Barbara L., Athale, Uma H., Clavell, Luis A., Cole, Peter D., Kelly, Kara M., Laverdiere, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Schorin, Marshall A., Sulis, Maria Luisa, Welch, Jennifer J.G., Neuberg, Donna S., Sallan, Stephen E., Silverman, Lewis B.

“…Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001 tested a new risk stratification system in children and adolescents with newly diagnosed…”
Get full text

Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols by BARRY, Elly, DEANGELO, Daniel J, SAMSON, Yvan, SCHORIN, Marshall, COHEN, Harvey J, SALLAN, Stephen E, SILVERMAN, Lewis B, NEUBERG, Donna, STEVENSON, Kristen, LOH, Mignon L, ASSELIN, Barbara L, BARR, Ronald D, CLAVELL, Luis A, HURWITZ, Craig A, MOGHRABI, Albert

“…Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children. We report the outcome of…”
Get full text

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 by Silverman, Lewis B., Gelber, Richard D., Dalton, Virginia Kimball, Asselin, Barbara L., Barr, Ronald D., Clavell, Luis A., Hurwitz, Craig A., Moghrabi, Albert, Samson, Yvan, Schorin, Marshall A., Arkin, Steven, Declerck, Lieven, Cohen, Harvey J., Sallan, Stephen E.

“…The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocol 91-01 was designed to improve the outcome of children with newly…”
Get full text

Pilot Studies towards Optimizing Quality of Life and Outcomes in Patients Post Left Ventricular Assist Device Implantation by Sajgalik, P., Kim, C., Wheatley-Guy, C., Clavell, A.L., Kushwaha, S.S., Stulak, J.M., Schettle, S.D., Cierzan, B.S., Schirger, J.A., Johnson, B.D.

“…For optimization of the pump setting, there is currently a lack of non-invasive diagnostic methods capable to sensitively reflect the altered right-to-left…”
Get full text

Effects of Aspirin on Progression of Cardiac Allograft Vasculopathy and Outcomes after Heart Transplantation by Asleh, R., Briasoulis, A., Smith, B., Lopez, C., Lerman, A., Pereira, N.L., Daly, R.C., Kremers, W.K., Clavell, A.L., Stulak, J.M., Kushwaha, S.S.

“…Enhanced platelet reactivity may play a role in the development and progression of cardiac allograft vasculopathy (CAV). Although aspirin is often a part of…”
Get full text

Combined Heart-Kidney Transplantation: Vasoplegia is Associated with Poorer Post-Kidney Transplant Outcomes by Steadman, J.A., Stulak, J.M., Clavell, A.L., Kushwaha, S.S., Edwards, B.S., Pereira, N.L., Dunlay, S.M., Schirger, J.A., Frantz, R.P., Smith, B.H., Dean, P.G., Daly, R.C.

“…Candidate selection for multi-organ transplants should consider the chances of good function and benefit of all transplanted organs. Risk factors for early…”
Get full text

Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane by BARRY, Elly V, VROOMAN, Lynda M, SCHORIN, Marshall A, COHEN, Harvey J, LIPSHULTZ, Steven E, SALLAN, Stephen E, SILVERMAN, Lewis B, DAHLBERG, Suzanne E, NEUBERG, Donna S, ASSELIN, Barbara L, ATHALE, Uma H, CLAVELL, Luis A, LARSEN, Eric C, MOGHRABI, Albert, SAMSON, Yvan

“…Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of…”
Get full text

The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia by Lipshultz, Steven E, Rifai, Nader, Dalton, Virginia M, Levy, Donna E, Silverman, Lewis B, Lipsitz, Stuart R, Colan, Steven D, Asselin, Barbara L, Barr, Ronald D, Clavell, Luis A, Hurwitz, Craig A, Moghrabi, Albert, Samson, Yvan, Schorin, Marshall A, Gelber, Richard D, Sallan, Stephen E

“…Doxorubicin is an efficacious treatment for childhood acute lymphoblastic leukemia (ALL), but it is toxic to myocardial cells and can cause cardiomyopathy. In…”
Get full text

Combined Heart and Kidney Transplantation Provides an Excellent Survival and Decreases Risk of Cardiac Cellular Rejection and Coronary Allograft Vasculopathy by Raichlin, E, Kushwaha, S.S, Daly, R.C, Kremers, W.K, Frantz, R.P, Clavell, A.L, Rodeheffer, R.J, Larson, T.S, Stegall, M.D, McGregor, C, Pereira, N.L, Edwards, B.S

“…Abstract Background We analyzed the results of combined heart-kidney transplantation (CHKTx) over a 10-year period. Methods Between September 1996 and May 2007…”
Get full text

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Tran, Thai Hoa, Harris, Marian H., Nguyen, Jonathan V., Blonquist, Traci M., Stevenson, Kristen E., Stonerock, Eileen, Asselin, Barbara L., Athale, Uma H., Clavell, Luis A., Cole, Peter D., Kelly, Kara M., Laverdiere, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Schorin, Marshall A., Welch, Jennifer J.G., Reshmi, Shalini C., Neuberg, Donna S., Sallan, Stephen E., Loh, Mignon L., Silverman, Lewis B.

“…Recurrent chromosomal rearrangements carry prognostic significance in pediatric B-lineage acute lymphoblastic leukemia (B-ALL). Recent genome-wide analyses…”
Get full text

Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia by Sulis, M.L., Blonquist, T.M., Stevenson, K.E., Hunt, S.K., Kay‐Green, S., Athale, U.H., Clavell, L.A., Cole, P.D., Kelly, K.M., Laverdiere, C., Leclerc, J.M., Michon, B., Schorin, M.A., Welch, J.G., Neuberg, D.S., Sallan, S.E., Silverman, L.B.

“…Background Pediatric patients receiving induction chemotherapy for newly diagnosed acute lymphoblastic leukemia (ALL) are at high risk of developing…”
Get full text

Cardiac Allograft Remodeling After Heart Transplantation Is Associated with Increased Graft Vasculopathy and Mortality by Raichlin, E., Villarraga, H. R., Chandrasekaran, K., Clavell, A. L., Frantz, R. P., Kushwaha, S. S., Rodeheffer, R. J., McGregor, C. G., Daly, R. C., Park, S. J., Kremers, W. K., Edwards, B. S., Pereira, N. L.

“…The aim of this study was to assess the patterns, predictors and outcomes of left ventricular remodeling after heart transplantation (HTX). Routine…”
Get full text

Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol by Lipshultz, S. E.

Get full text

Height and Weight in Children Treated for Acute Lymphoblastic Leukemia: Relationship to CNS Treatment by DALTON, Virginia Kimball, RUE, Montse, SCHORIN, Marshall, TARBELL, Nancy J, SALLAN, Stephen E, COHEN, Laurie E, SILVERMAN, Lewis B, GELBER, Richard D, ASSELIN, Barbara L, BARR, Ronald D, CLAVELL, Luis A, HURWITZ, Craig A, MOGHRABI, Albert, SAMSON, Yvan

“…We evaluated the long-term effects of treatment on height and weight in children with acute lymphoblastic leukemia (ALL) treated with one of the following…”
Get full text